Iroko Pharmaceuticals's Submicron NSAIDs Demonstrate Efficacy at Lower Doses in Studies in Patients With Acute and Chronic Pain

PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC, a Philadelphia-based pharmaceutical company focused on the development and commercialization of innovative therapeutic products, is presenting positive Phase 3 data from its investigational submicron non-steroidal anti-inflammatory drug (NSAID) pipeline at two medical meetings. These presentations summarize the results of studies of lower dose submicron indomethacin in patients with post surgical pain, and lower dose submicron diclofenac in patients with osteoarthritis pain. Both studies met their primary endpoints of providing significant pain relief compared with placebo.